Orexin Modulation of VTA Dopamine Neuron Activity: Relevance to Schizophrenia

Stephanie M. Perez, Daniel J. Lodge

Department of Pharmacology and Center for Biomedical Neuroscience, University of Texas Health Science Center, San Antonio, TX, USA (Drs Perez and Lodge) and South Texas Veterans Health Care System, Audie L. Murphy Division, USA (Dr Lodge).

Correspondence: Stephanie M. Perez, PhD, 7703 Floyd Curl Drive, MC 7764, San Antonio, TX, 78229, USA (perezsm@uthscsa.edu).

Abstract

Background: The hippocampus is a region consistently implicated in schizophrenia and has been advanced as a therapeutic target for positive, negative, and cognitive deficits associated with the disease. Recently, we reported that the paraventricular nucleus of the thalamus (PVT) works in concert with the ventral hippocampus to regulate dopamine system function; however, the PVT has yet to be investigated as target for the treatment of the disease. Given the dense expression of orexin receptors in the thalamus, we believe these to be a possible target for pharmacological regulation of PVT activity.

Methods: Here we used the methylazoxymethanol acetate (MAM) rodent model, which displays pathological alterations consistent with schizophrenia to determine whether orexin receptor blockade can restore ventral tegmental area dopamine system function. We measured dopamine neuron population activity, using in vivo electrophysiology, following administration of the dual orexin antagonist, TCS 1102 (both intraperitoneal and intracranial into the PVT in MAM- and saline-treated rats), and orexin A and B peptides (intracranial into the PVT in naïve rats).

Results: Aberrant dopamine system function in MAM-treated rats was normalized by the systemic administration of TCS 1102. To investigate the potential site of action, the orexin peptides A and B were administered directly into the PVT, where they significantly increased ventral tegmental area dopamine neuron population activity in control rats. In addition, the direct administration of TCS 1102 into the PVT reproduced the beneficial effects seen with the systemic administration in MAM-treated rats.

Conclusion: Taken together, these data suggest the orexin system may represent a novel site of therapeutic intervention for psychosis via an action in the PVT.

Key Words: Schizophrenia, paraventricular nucleus of the thalamus, orexins, dopamine

Introduction

The ventral hippocampus (vHipp) and paraventricular nucleus of the thalamus (PVT) have been demonstrated to work in concert to regulate the activity of the mesolimbic dopamine system via a polysynaptic circuit involving the nucleus accumbens (NAc), ventral pallidum (VP), and ventral tegmental area (VTA) (Floresco et al., 2001; Perez and Lodge, 2018). Individuals with schizophrenia display baseline hyperactivity in select hippocampal subregions, which is correlated with symptom severity (Heckers, 2001, 2004; Schobel et al., 2009). Similarly, rodent models used to study this disorder also display elevated baseline activity in the vHipp, which is directly responsible for an increase in dopamine neuron population activity (defined as the number of spontaneously active dopamine neurons) in the VTA (Lodge and Grace, 2007; Aguilar, 2014; Perez et al., 2016; Perez and Lodge, 2018, 2019). The PVT, much like the vHipp, can regulate VTA dopamine neuron activity, without affecting average firing rate.
or bursting, via an indirect pathway involving the NAc and VP (see Figure 1) (Perez and Lodge, 2018). Further, activity in the vHipp is required for PVT-induced increases in dopamine neuron population activity, with the converse also being true (Perez and Lodge, 2018). Studies have demonstrated prominent glutamatergic projections from the PVT to the NAc (Su and Bentivoglio, 1990; Bubser and Deutch, 1998; Pinto et al., 2003; Dong et al., 2017). Indeed, convergent inputs from the vHipp and PVT onto medium spiny neurons of the NAc work in concert to regulate VTA dopamine activity (see Figure 1) (Perez and Lodge, 2018). In addition, the PVT can regulate dopamine system function by direct modulation of dopamine terminals within the NAc (Perez and Lodge, 2018). These data suggest that the PVT may be a novel site of intervention for the treatment of psychosis in schizophrenia. Indeed, pharmacological or chemogenetic inactivation of the PVT can restore normal dopamine system function in different rodent models used to study schizophrenia (Perez and Lodge, 2018).

A unique characteristic of the PVT is the dense and robust peptidergic innervation, including those by the orexin/hypocretin (ORX) peptides, which are of particular importance to this study (Kirouac, 2015). PVT neurons are dose dependently excited by orexin peptides A (OXA) and B (OXB) (Ishibashi et al., 2005). OXA and OXB are ligands of the G-protein–coupled receptors, orexin 1 and orexin 2, and display differential affinities such that OX1R has a higher affinity for OXA (EC50 30 nM) than OXB (EC50 250 nM), whereas OX2R is equally sensitive to OXA (EC50 34 nM) and OXB (EC50 60 nM). Activation of these receptors excites target neurons through various second messenger systems (Kukkonen, 2013) and can directly (Nakamura et al., 2000) and indirectly (Perez and Lodge, 2018) modulate VTA dopamine system function. Additionally, orexin peptides produce dose-dependent increases in the firing rates of PVT neurons (Ishibashi et al., 2005), and these neurons can regulate dopamine levels in the NAc (Parsons et al., 2007). Dysfunction of the dopamine system has long been associated with positive symptoms of schizophrenia (i.e., psychosis) (Abi-Dargham et al., 1998; Laruelle and Abi-Dargham, 1999; Abi-Dargham, 2004; Howes et al., 2012). Taken together, we posit that targeting ORX receptors in the PVT can reverse the dysfunction present in the mesolimbic dopamine system commonly observed in preclinical models of the disease and, potentially, in individuals with schizophrenia. Here, we used a dual orexin receptor antagonist, TCS 1102, to evaluate whether this approach can normalize aberrant VTA dopamine neuron population activity in rats treated with methyIxazoxymethanol acetate (MAM), a gestational disruption that models some of the pathological alterations of schizophrenia (Moore et al., 2006; Lodge and Grace, 2009). This compound was specifically chosen because it blocks both OX1R and OX2R and has been shown to effectively block orexin-mediated behaviors for up to 4 hours (Bergman et al., 2008; Winrow et al., 2010). Moreover, similar compounds are already approved by the FDA for the treatment of sleep disorders. Here, we provide evidence that targeting the ORX system may be a novel approach for the treatment of psychosis in schizophrenia.

Materials and Methods
All experiments were performed in accordance with the guidelines outlined in the USPH Guide for the Care and Use

**Significance Statement**
Available pharmacological therapies for the treatment of schizophrenia are not always effective and produce undesirable side effects. For these reasons, patients with schizophrenia often discontinue antipsychotic treatments; thus, better medications are needed to adequately treat this devastating psychiatric disorder. Here, we demonstrate that the orexin system, via an action in the paraventricular nucleus of the thalamus, may represent a novel therapeutic target for the treatment of psychosis.
of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee of UT Health San Antonio.

Animals
All experiments were performed on multiple litters of adult (>12 weeks) male MAM- and saline-treated rats, as previously described (Moore et al., 2006; Lodge, 2013). In brief, timed-pregnant female Sprague-Dawley rats were obtained from Envigo RMS Inc. (Indianapolis, IN) on gestational day (GD) 16. MAM (diluted in saline, 22 mg/kg i.p.) was administered on GD17, while control rats received injections of saline (1 mL/kg, i.p.). Pups were weaned on post-natal day 21 and housed with littermates in groups of 2–3 rats per cage. A separate set of experiments was performed on untreated adult male Sprague-Dawley rats obtained from Envigo.

Drug Administration
For systemic drug administration, TCS 1102 (10 mg/kg; Chen et al., 2014; Ki values were 3.0 and 0.2 nM for OXR1 and OXR2, respectively) or vehicle (60% dimethyl sulfoxide in saline; 1 mL/kg) was administered i.p. (MAM- or saline-treated rats) 15 minutes prior to any electrophysiological recordings. Although the half-life of TCS 1102 is relatively short (approximately 20 minutes), behavioral responses are observed for up to 4 hours following administration (Bergman et al., 2008), which is consistent with the average time to complete VTA recordings for a single animal (2–3 hours). For unilateral intracranial drug administration, a 26-gauge guide cannula (Plastics One, Roanoke County, VA) was lowered into/immediately adjacent to the VTA (A/P −2.0 mm, M/L +0.4 mm from bregma and D/V −5.8 mm ventral of the brain surface) to avoid damage to the relatively small structure as previously reported (Perez and Lodge, 2018). An internal cannula (Plastics One), extending 1 mm past the end of the guide cannula, was used to deliver a 1-time injection of vehicle, peptides (OXA or OXB: 3 µg/750 nL; untreated SD rats), or TCS 1102 (1.5 µg/0.5 µL; MAM- or saline-treated rats) at a rate of approximately 0.5 µL/min at 10 minutes prior to any electrophysiological recording.

Extracellular Dopamine Neuron Recordings
Male rats (approximately 300–450 g) were anesthetized with 8% chloral hydrate (400 mg/kg, i.p.), as this anesthetic does not significantly depress dopamine neuron activity (Hyland et al., 2002). Anesthesia was maintained by supplemental administration of chloral hydrate as required to maintain suppression of limb compression withdrawal reflex. Rats were positioned in a stereotaxic apparatus (Kopf, Tujunga, CA), and a core body temperature of 37°C was maintained by a thermostatically controlled heating pad (Kent Scientific, Torrington, CT). Extracellular glass microelectrodes (impedance: 6–14 MΩ) were lowered into the VTA (A/P ± 5.3 mm, M/L ± 0.6 mm from bregma and D/V −5.8 to −9.0 mm ventral of the brain surface) using a hydraulic micro-positioner (Kopf, Model 640) to measure dopamine neuron activity. Spontaneously active dopamine neurons were recorded for a period of 2–3 minutes and identified with open filter settings (low pass: 30 Hz; high pass: 30 kHz) using previously established electrophysiological criteria (Grace and Bunney, 1983). We measured 3 parameters of dopamine neuron activity: (1) population activity (defined as the number of spontaneously active dopamine neurons encountered while making 6–9 tracks or dorsal/ventral vertical passes), separated by 200 µm in a predetermined pattern to sample equivalent regions of the VTA; (2) basal firing rate; and (3) the proportion of action potentials occurring in bursts. At the cessation of all electrophysiological recordings, rats were rapidly decapitated.

Analysis
Electrophysiological analysis of dopamine neuron activity was performed using commercially available computer software (LabChart version 7.1; ADInstruments Ltd., Chalgrove, Oxfordshire, UK) and plotted with Prism software (GraphPad Software Inc., San Diego, CA). Electrophysiological data was analyzed by 1-way ANOVA, 2-way ANOVA (strain × treatment) with post hoc comparisons performed using the Holm-Sidak method, or Kruskal-Wallis 1-way ANOVA on ranks with post hoc comparisons performed using Dunn’s method. Data are represented as the mean ± SEM unless otherwise stated, with n values representing the number of rats per group or neurons recorded per experimental group where indicated. Significance was determined at P < .05. All statistics were calculated using SigmaPlot (Systat Software, Chicago, IL).

Materials
MAM was purchased from Midwest Research Institute (Kansas City, MO). TCS 1102 was purchased from Tocris (Cat. No. 3818; Minneapolis, MN). Orexin B was purchased from R & D systems (Catalog # 1457; Minneapolis, MN), and Orexin A was sourced from Cayman Chemicals (Item No. 15073; Ann Arbor, MI). Chloral hydrate was sourced from Sigma-Aldrich (St. Louis, MO). All other chemicals and reagents were of either analytical or laboratory grade and purchased from standard suppliers.

Results
TCS 1102, a Dual Orexin Antagonist, Reverses Aberrant VTA Dopamine Neuron Population Activity
We used TCS 1102 to examine whether blockade of orexin signaling could modulate VTA dopamine neuron activity in MAM-treated rats (Figure 2A). Similar to previous reports, SD control rats (n = 7 rats) displayed a population activity of 1.02 ± 0.04 cells per track, and MAM-treated rats (n = 8 rats) displayed a significantly higher population activity (1.77 ± 0.10 cells per track; 2-way ANOVA; F (1, 26) = 15.52; P < .001; Tukey’s post hoc; t = 6.79; P < .001). The i.p. administration of TCS 1102 had no effect on saline-treated rats (n = 6 rats; 1.05 ± 0.07 cells per track); however, it restored normal VTA dopamine system function in MAM-treated rats (n = 6 rats; 1.08 ± 0.08 cells per track; Holm-Sidak post hoc; t = 5.93; P < .001). Consistent with previous reports, saline-treated vehicle rats displayed an average firing rate of 3.97 ± 0.24 Hz (n = 45 neurons; Figure 2B). The average firing rate of MAM-treated rats also treated with TCS 1102 (n = 38 neurons; 3.24 ± 0.31 Hz) displayed a significant decrease compared with control MAM-treated rats (n = 83 neurons; 4.52 ± 0.23 Hz; 2-way ANOVA; F (1, 202) = 8.53; P = .004; Holm-Sidak post hoc; t = 3.19; P = .002) and saline-treated rats administered TCS 1102 (n = 37 neurons; 4.46 ± 0.40 Hz; Holm-Sidak post hoc; t = 2.59; P = .01). No significant differences were observed in the average percent bursting between any of the groups (Figure 2C; saline: n = 45 neurons; 36.12 ± 3.93% bursting; MAM-vehicle: n = 83 neurons; 38.97 ± 3.08% bursting; saline-TCS 1102: n = 37 neurons; 44.40 ± 4.77% bursting; MAM-TCS 1102: n = 38 neurons; 36.15 ± 4.56% bursting).
Orexin Peptides A and B in the PVT Increase VTA Dopamine Neuron Population Activity

To determine whether orexin modulation of the PVT regulates VTA dopamine neurons, we unilaterally injected exogenous OXA and OXB peptides into the PVT (Figure 3A). Consistent with previous reports in Sprague-Dawley control rats, rats injected with vehicle displayed an average population activity of 1.01 ± 0.05 cells per track (n = 8 rats). Intra-PVT administration of the exogenous peptides, OXA (n = 5 rats; 1.95 ± 0.15 cells per track) or OXB (n = 6 rats; 1.92 ± 0.07 cells per track), caused a significant increase in population activity compared with control rats (1-way ANOVA; F(2, 18) = 42.69; \( P < .001 \); Holm-Sidak post hoc; OXA: \( t = 7.69; P < .001 \); OXB: \( t = 7.81; P < .001 \)). No significant differences were observed in the average firing rate (Figure 3B; Kruskal-Wallis 1-way ANOVA on ranks; control: n = 56 neurons; 4.22 ± 0.27 Hz; OXA: n = 60 neurons; 4.26 ± 0.43 Hz; OXB: n = 65 neurons; 4.85 ± 0.31 Hz) or average percent bursting (Figure 3C; Kruskal-Wallis 1-way ANOVA on ranks; control: n = 56 neurons; 30.03 ± 3.27% bursting; OXA: n = 60 neurons; 32.26 ± 3.43% bursting; OXB: n = 65 neurons; 34.19 ± 3.23% bursting) between any of the groups. Representative dopamine recording and action potential from a saline-treated vehicle (D), MAM-treated vehicle (E), saline-treated TCS 1102 (F), and MAM-treated TCS 1102 (G) rats.

TCS 1102 in the PVT Restores VTA Dopamine Neuron Population Activity

To determine whether orexin receptor blockade in the PVT could reverse aberrant VTA dopamine neuron population activity in MAM-treated rats, we unilaterally injected TCS 1102 or vehicle into the PVT of MAM- or saline-treated rats (Figure 4A). Consistent with previous reports in Sprague-Dawley control rats, saline-treated rats injected with vehicle displayed an average population activity of 1.01 ± 0.05 cells per track (n = 8 rats). MAM-treated rats injected with vehicle displayed a significant increase in population activity (n = 6 rats; 1.67 ± 0.06 cells per track) compared with saline-treated controls (2-way ANOVA; \( F_{(1,23)}^{(strain)} = 13.79; P = .001 \); \( F_{(1,23)}^{(treatment)} = 12.74; P = .002 \);
Intra-PVT administration of TCS 1102 caused a significant decrease in population activity in MAM-treated rats (\(n = 5\) rats; \(1.02 \pm 0.06\) cells per track) compared with MAM-treated control rats (Holm-Sidak post hoc; \(t = 5.69; P < .001\)). No changes in population activity were observed in saline-treated rats injected with TCS 1102 in the PVT (\(n = 5\) rats; \(1.10 \pm 0.15\) cells per track). Vehicle MAM-treated rats (\(n = 60\) neurons; \(5.27 \pm 0.36\) Hz; \(49.27 \pm 3.57\%\) burst firing) displayed an elevated firing rate (Figure 4B) and bursting pattern (Figure 4C) compared with saline-treated vehicle control rats (\(n = 56\) neurons; \(4.22 \pm 0.27\) Hz; \(2\)-way ANOVA; Holm-Sidak post hoc; \(t = 2.50; P = .01; 30.03 \pm 3.27%\) burst firing; \(t = 3.90; P < .001\)) and MAM-treated rats injected with TCS 1102 in the PVT (\(n = 33\) neurons; \(3.94 \pm 0.29\) Hz; \(2\)-way ANOVA; Holm-Sidak post hoc; \(t = 2.73; P = .007; 31.37 \pm 4.54%\) burst firing; \(t = 3.11; P < .001\)). TCS 1102 injected in the PVT had no effect on saline-treated rats (\(n = 29\) neurons; \(3.65 \pm 0.39\) Hz; \(36.11 \pm 5.31%\) burst firing).

**Discussion**

The thalamus serves as a major point of convergence for various neuronal circuits and is composed of several nuclei, each with distinct afferent and efferent projections (Andreasen et al., 1994; Byne et al., 2009). Moreover, thalamic abnormalities have been previously implicated in schizophrenia (Pergola et al., 2015). Specifically, a decrease in the thalamic volume and reduced gray matter has been reported in schizophrenia patients compared with healthy controls (Andreasen et al., 1994; Buchsbaum et al., 1996; Gilbert et al., 2001; McDonald et al., 2005; Glahn et al., 2008;
Fornito et al., 2009). Furthermore, positron emission tomography studies performed in individuals with schizophrenia report abnormal activation of the thalamus during active auditory hallucinations (Andreasen et al., 1992) and decreased thalamic blood flow (Andreasen et al., 1996; Andreasen, 1997). However, the exact role of discrete thalamic nuclei in schizophrenia remains unclear, and it is not currently known whether the structural and functional alterations observed in this disease are a consequence of, or contribute to, the symptoms of schizophrenia (Sim et al., 2006; Keedy et al., 2009; Pergola et al., 2015).

Of importance to this study is the PVT and its innervation of the NAc (Moga et al., 1995; Pinto et al., 2003; Kirouac, 2015; Dong et al., 2017). The PVT sends direct and indirect projections to dopamine neurons within the VTA (Zahm and Heimer 1990; Zahm 2000) and synapse on both medium spiny neurons and dopamine terminals within the NAc (Pinto et al., 2003; Perez and Lodge, 2018). Thus, in addition to direct modulation of NAc neurons, the PVT can regulate presynaptic dopamine release (Pinto et al., 2003; Parsons et al., 2007). Indeed, it has been reported that glutamate release from PVT terminals can act on ionotropic glutamate receptors to induce dopamine efflux in the NAc (Parsons et al., 2007). Thus, a decrease in PVT activity, by orexin receptor blockade, may decrease dopamine signaling multiple mechanisms, including (1) a direct effect on presynaptic release, and (2) an indirect effect on dopamine neuron activity in the VTA. We recently demonstrated that pharmacological (N-methyl-D-aspartate) activation of the PVT induces an increase in VTA dopamine neuron population activity without affecting the firing rate or bursting pattern of these neurons (Perez and Lodge, 2018), as those measures are altered by manipulations to other brain regions (Murase et al., 1993; Floresco et al., 2003). Indeed, this is consistent with previous studies examining the regulation of VTA dopamine neurons by the vHipp, in which activation of the vHipp produced selective increases in dopamine neuron population activity (Lodge and Grace, 2007). Interestingly, this PVT-induced increase in population activity is dependent on glutamatergic projections to the NAc, as chemogenetic activation of the PVT-NAc pathway produces a similar increase in dopamine neuron population activity (Perez and Lodge, 2018). Further, inactivation of the PVT was able to reverse aberrant dopamine neuron activity thought to contribute to psychosis in schizophrenia (Perez and Lodge, 2018).

Figure 4. Intracranial microinjection of the dual orexin antagonist, TCS 1102, into the paraventricular nucleus of the thalamus (PVT), restored normal dopamine system function in MAM-treated rats (A). *P < .001 denotes significance from saline-treated vehicle. †P < .001 denotes significance from MAM-treated vehicle. TCS 1102 administration attenuated the average firing rate (B) and average percent bursting (C) in MAM-treated vehicle rats. ‡P < .05 denotes significance from saline-treated vehicle. ††P < .05 denotes significance from MAM-treated vehicle. Representative dopamine recording and action potential from a saline-treated TCS 1102 (D) and MAM-treated TCS 1102 (E) rats.
The PVT receives a dense innervation from the ORX system (Kirouac, 2015) and can directly (via direct innervation of dopaminergic neurons of the VTA (Nakamura et al., 2000) or indirectly (via projections to the NAc (Perez and Lodge, 2018) modulate dopamine system function. Thus, we used the MAM rodent model, which displays neurophysiological and behavioral deficits consistent with schizophrenia to examine whether targeting the ORX system could reverse the mesolimbic dopamine system dysfunction, commonly observed in individuals with schizophrenia. As mentioned previously, numerous rodent models used to study the neurobiology of schizophrenia exhibit a significant increase in dopamine neuron population activity (Lodge and Grace, 2007; Shah and Lodge, 2013; Aguilar, 2014; Boley et al., 2014; Perez et al., 2016, 2019a, 2019b). We observed a similar increase in MAM-treated vehicle rats, as they displayed a significant increase in VTA dopamine neuron population activity compared with saline-treated vehicle rats. Importantly, TCS 1102 administration was able to restore normal dopamine system function in MAM-treated rats, demonstrating that the ORX system may be a therapeutic target (Figure 2A). It should be noted that MAM-treated rats treated with TCS 1102 displayed a slight decrease in the average firing rate of VTA dopamine neurons compared with MAM-treated vehicle rats and saline-treated rats administered TCS 1102 (Figure 2B). Although we did observe this significant difference, it is likely that only subpopulations of dopamine neurons are affected. The ORX system has been demonstrated to facilitate dopamine neuron activity and fluctuations in ORX levels and can influence the excitability of VTA dopamine activity (Moorman and Aston-Jones 2010). Thus, direct effects of the ORX antagonist on dopamine neurons are possible; however, the dramatic effects on population activity are likely attributable to indirect regulation.

Orexin peptides play a role in wakefulness and have been demonstrated to increase arousal and locomotor activity (Hagan et al., 1999; Alexandre et al., 2013). Although some antipsychotics have sedative effects on patients, this is often related to the dose and the sedative effect is not thought to contribute to the mechanism of action (Miller 2004; Muench and Hamer, 2010). Indeed, other compounds that affect arousal, such as benzodiazepines, are not effective nonmotor therapies (Dell’osso and Lader 2013); therefore, it is likely that the results here are indicative of changes in the regulation of dopamine system function rather than nonselective changes in arousal. Further, it should be noted that the PVT has been shown to be activated after stressful or aversive events (Bubser and Deutch, 1999; Penzo et al., 2015). Interestingly, stress is also a known risk factor for a number of psychiatric conditions, including schizophrenia, suggesting that the PVT might be a potential site of convergence for stress-related psychiatric disorders (Day et al., 1987; Malla et al., 1990). To determine whether ORX system modulation could increase VTA dopamine neuron population activity via the PVT, we performed direct microinjections of the OXA or OXB peptides and recorded VTA dopamine neuron activity (Figure 3). We evaluated the efficacy of OXA and OXB in modulating VTA dopamine neuron activity, as they differentially target OX1R (binds OXA) and OX2R (binds OXA and OXB), both of which are similarly expressed in the PVT (Marcus et al., 2001). Studies have reported activation of the dopamine system by orexins (Nakamura et al., 2000) and that these peptides produce excitatory effects in the PVT (Ishibashi et al., 2005). Interestingly, infusion of either OXA or OXB into the PVT produced a significant increase in dopamine neuron population activity (Figure 3A), similar to what has been reported in rodent models used to study schizophrenia (Lodge and Grace, 2007; Perez et al., 2016, 2019a, 2019b). This increase was not observed in rodents that received vehicle infusions in the PVT, consistent with previous observations in control rats (Lodge and Grace, 2007; Perez et al., 2016, 2019a, 2019b). The ORX peptides were microinjected into or immediately adjacent to the PVT (Figure 3B) to avoid damage to the relatively small structure; thus, it is important to note that it is possible that other structures adjacent to the PVT may have been affected. Specifically, diffusion of the ORX peptides into the medial dorsal nucleus of the thalamus, immediately adjacent to the PVT, was likely; however, given that the density of ORX receptors in this region are very low, we do not believe this region to be modulated by OXR peptide infusion (Marcus et al., 2001). These data support previous chemogenetic studies targeting the PVT-NAc pathway (Perez and Lodge, 2018) and suggest that orexins can modulate mesolimbic dopamine neuron population activity via the PVT.

Lastly, to demonstrate that the effects of TCS 1102 on VTA dopamine neuron activity were indeed mediated by antagonizing orexin receptors, specifically in the PVT, we microinjected TCS 1102 into the PVT of MAM- and saline-treated rats and recorded the activity of VTA dopamine neurons. The significant increase in dopamine neuron population activity consistently observed MAM-treated rats was indeed reversed by local orexin receptor blockade in the PVT. This is consistent with a previous study that used chemogenetics to activate the PVT-NAc or the PVT-mPFC pathway and found that PVT-NAc activation was able to increase VTA dopamine neuron activity (Perez and Lodge, 2018). Thus, we posit that the effect observed in the current study is indeed specific to an action in the PVT. Further, it is likely that the ORX modulation occurs through an indirect pathway (Figure 1) involving the PVT and the NAc-VP-VTA polysynaptic circuit. These data validate the action of ORX in modulating and restoring dopamine system function in a model with relevance to schizophrenia.

Collectively, these data suggest that targeting the ORX system could be beneficial in restoring normal dopamine system function and eliminating symptoms of psychosis linked to dysfunction of that system. Further, data collected in this study support the idea that the FDA-approved dual orexin receptor antagonist, Suvorexant, may also treat symptoms of psychosis in individuals with schizophrenia. Suvorexant, at high doses, is effective at treating insomnia (Rhyne and Anderson 2015); however, lower, nonsedative doses could be effective at treating psychotic symptoms. Future studies will be aimed at observing the consequences of ORX modulation on behaviors associated with positive, negative, and cognitive symptom domains displayed by rodent models of schizophrenia. Indeed, activation of orexin neurons has been previously linked to improvements in working memory (Hahn et al., 2003; Pasumarthi and Fadel, 2008; Stanojlovic et al., 2019) as well as symptoms often comorbid with schizophrenia, such as anxiety (Li et al., 2010; Heydendael et al., 2014), depression (Arendt et al., 2013), and sleep disorders (Mieda and Sakurai 2013) (for orexin system review, see Chieffi et al., 2017). Further studies will explore the relative contributions of OX1R and OX2R separately, using an antagonist specific for each receptor. Therefore, this study provides evidence that the PVT is a potential site of intervention in schizophrenia and that targeting the ORX system may be a novel therapeutic approach for the treatment of psychosis.

Acknowledgments

This work was supported by Merit Award #B2004693 from the United States Department of Veterans Affairs, Biomedical Laboratory Research and Development Service, the National
Institutes of Health (RO1-MH090067), and the San Antonio Life Science Institute (SALSI Postdoctoral Scholar Fellowship to S.M.P.).

Statement of Interest
The authors declare no competing financial interests. D.J.L. received research funds from Heptares that are unrelated to the research here.

References
Abi-Dargham A (2004) Do we still believe in the dopamine hypothesis? New data bring new evidence. Int J Neuropsychopharmacol 7 Suppl 1:S1–S5.

Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, van Dyck CH, Charney DS, Innis RB, Laruelle M (1998) Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 155:761–767.

Aguilar DD, Chen L, Lodge DJ (2014) Increasing endocannabinoid levels in the ventral pallidum restores aberrant dopamine neuron activity in the subchronic PCP rodent model of schizophrenia. Int J Neuropsychopharmacol 18:pyu035.

Alexandre C, Andermann ML, Scammell TE (2013) Control of arousal by the orexin neurons. Curr Opin Neurobiol 23:752–759.

Andreasen NC (1997) The role of the thalamus in schizophrenia. Can J Psychiatry 42:27–33.

Andreasen NC, Rezai K, Alliger R, Swayze VW 2nd, Flaim M, Kirchner P, Cohen G, O’Leary DS (1992) Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with xenon 133 single-photon emission computed tomography and the Tower of London. Arch Gen Psychiatry 49:943–958.

Andreasen NC, Arndt S, Swayze V 2nd, Cizadlo T, Flaim M, O’Leary D, Ehrhardt JC, Yuh WT (1994) Thalamic abnormalities in schizophrenia visualized through magnetic resonance image averaging. Science 266:294–298.

Andreasen NC, O’Leary DS, Cizadlo T, Arndt S, Rezai K, Ponto LL, Watkins GL, Hichwa RD (1996) Schizophrenia and cognitive dysmetria: a positron-emission tomography study of dysfunctional prefrontal-thalamic-cerebellar circuitry. Proc Natl Acad Sci U S A 93:9985–9990.

Arendt DH, Ronan PJ, Oliver RD, Callahan LB, Summers TR, Summers CH (2013) Depressive behavior and activation of the orexin/hypocretin system. Behav Neurosci 127:86–94.

Bergman JM, Roeker AJ, Mercer SP, Bednar RA, Reiss DR, Ransom RW, Meacham Harrell C, Pettibone DJ, Lemaire W, Murphy KL, Li C, PrieurIsatant T, Winrow C, Renger JJ, Koblan KS, Hartman GD, Coleman PJ (2008) Proline bis-amides as potent dual orexin receptor antagonists. Bioorg Med Chem Lett 18:1425–1430.

Boyle AM, Perez SM, Lodge DJ (2014) A fundamental role for hippocampal parvalbumin in the dopamine hyperfunction associated with schizophrenia. Schizophr Res 157:238–243.

Bubser M, Deutch AY (1998) Thalamic paraventricular nucleus neurons collateralize to innervate the prefrontal cortex and nucleus accumbens. Brain Res 787:304–310.

Bubser M, Deutch AY (1999) Stress induces Fos expression in neurons of the thalamic paraventricular nucleus that innervate limbic forebrain sites. Synapse 32:13–22.

Buchsbaum MS, Someya T, Teng CY, Abel L, Chin S, Najafi A, Haier RJ, Wu J, Bunney WE Jr (1996) PET and MRI of the thalamus in never-medicated patients with schizophrenia. Am J Psychiatry 153:191–199.

Byne W, Hazlett EA, Buchsbaum MS, Kemether E (2009) The thalamus and schizophrenia: current status of research. Acta Neuropathol 117:347–368.

Chen X, Wang H, Lin Z, Li S, Li Y, Bergen HT, Vrontakis ME, Kirouac GJ (2014) Orexins (hypocretins) contribute to fear and avoidance in rats exposed to a single episode of footshocks. Brain Struct Funct 219:2103–2118.

Chieffi S, Carotenuto M, Monda V, Valenzano A, Villano I, Frecenzano F, Tafari D, Salerno M, Filippi N, Nuccio F, Roberto M, De Luca V, Cipolloni L, Cibelli G, Mollica MP, Iacono D, Nigro E, Monda M, Messina G, Messina A (2017) Orexin system: the key for a healthy life. Front Physiol 8:357.

Day R, Nielsen JA, Korten A, Ernberg G, Dube KC, Gebhart J, Jablensky A, Leon C, Marsella A, Olatwawura M (1987) Stressful life events preceding the acute onset of schizophrenia: a cross-national study from the World Health Organization. Cult Med Psychiatry 11:123–205.

Dell’osso B, Lader M (2013). “Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A critical reappraisal,” Eur Psychiatry 28:7–20.

Dong X, Li S, Kirouac GJ (2017). “Collateralization of projections from the paraventricular nucleus of the thalamus to the nucleus accumbens, bed nucleus of the stria terminalis, and central nucleus of the amygdala.” Brain Struct Funct 222:3927–3943.

Floresco SB, Todd CL, Grace AA (2001) Glutamatergic afferents from the hippocampus to the nucleus accumbens regulate activity of ventral tegmental area dopamine neurons. J Neurosci 21:4915–4922.

Floresco SB, West AR, Ash B, Moore H, Grace AA (2003) Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmission. Nat Neurosci 6:968–973.

Fornito A, Yücel M, Patti J, Wood SJ, Pantelis C (2009) Mapping grey matter reductions in schizophrenia: an anatomical likelihood estimation analysis of voxel-based morphometry studies. Schizophr Res 108:104–113.

Gilbert AR, Rosenberg DR, Harenki S, Spencer S, Sweeney JA, Keshavan MS (2001) Thalamic volumes in patients with first-episode schizophrenia. Am J Psychiatry 158:618–624.

Glahn DC, Laird AR, Ellison-Wright I, Thelen SM, Robinson JL, Lancaster JL, Bullmore E, Fox PT (2008) Meta-analysis of gray matter anomalies in schizophrenia: application of anatomic likelihood estimation and network analysis. Biol Psychiatry 64:774–781.

Grace AA, Bunney BS (1983) Intracellular and extracellular electrophysiology of nigral dopaminergic neurons–1. Identification and characterization. Neuroscience 10:301–315.

Grace AA, Floresco SB, Goto Y, Lodge DJ (2007) Regulation of firing of dopaminergic neurons and control of goal-directed behaviors. Trends Neurosci 30:220–227.

Hagan JJ, et al. (1999) Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc Natl Acad Sci U S A 96:10911–10916.

Hahn B, Shoaib M, Stolerman IP (2003) Involvement of the prefrontal cortex but not the dorsal hippocampus in the attention-enhancing effects of nicotine in rats. Psychopharmacology 168:271–279.

Heckers S (2001) Neuroimaging studies of the hippocampus in schizophrenia. Hippocampus 11:520–528.

Heckers S (2004) The hippocampus in schizophrenia. Am J Psychiatry 161:2138–2139.

Heydendael W, Sengupta A, Beck S, Bhattachar J (2014) Optogenetic examination identifies a context-specific role
for orexins/hypocretins in anxiety-related behavior. Physiol Behav 130:182–190.

Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M, Abidargham A, Kapur S (2012) The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry 69:776–786.

Hyland BI, Reynolds JN, Hay J, Perk CG, Miller R (2002) Firing modes of midbrain dopamine cells in the freely moving rat. Neuroscience 114:475–492.

Ishibashi M, Takeo S, Yanagida H, Takatsuna M, Nakajima K, Oomura Y, Wayner MF, Sasaki K (2005) Effects of orexins/hypocretins on neuronal activity in the paraventricular nucleus of the thalamus in rats in vitro. Peptides 26:471–481.

Keedy SK, Rosen C, Khine T, Rajarethinam R, Janicak PG, Sweeney JA (2009) An fMRI study of visual attention and sensorimotor function before and after antipsychotic treatment in first-episode schizophrenia. Psychiatry Res 172:16–23.

Kirovac GJ (2015) Placing the paraventricular nucleus of the thalamus within the brain circuits that control behavior. Neurosci Biobehav Rev 56:315–329.

Kukkonen JP (2013) Physiology of the orexinergic/hypocretinergic system: a revisit in 2012. Am J Physiol Cell Physiol 304:C2–C32.

Laruelle M, Abi-Dargham A (1999) Dopamine as the wind of the muscarimotor function before and after antipsychotic treatment in first-episode schizophrenia. Neurors Biobehav Rev 56:315–329.

Li Y, Li S, Wei C, Wang H, Sui N, Kirouac GJ (2010) Orexins in the paraventricular nucleus of the thalamus mediate anxiety-like responses in rats. Psychopharmacology (Berlin) 212:251–265.

Lodge DJ (2013) The MAM rodent model of schizophrenia. Curr Protoc Neurosci Chapter 9:Unit 9.43: 63. 9:43.1–9:43.7.

Lodge DJ, Grace AA (2007) Aberrant hippocampal activity underlies the dopamine dysregulation in an animal model of schizophrenia. J Neurosci 27:11424–11430.

Lodge DJ, Grace AA (2009) Gestational methyloxazymethanol acetate administration: a developmental disruption model of schizophrenia. Behav Brain Res 204:306–312.

Malla AK, Cortese L, Shaw TS, Ginsberg B (1990) Life events and relapse in schizophrenia. A one year prospective study. Soc Psychiatry Psychiatr Epidemiol 25:221–224.

Marcus JN, Aschkenasi CJ, Lee CE, Chemelli RM, Saper CB, Yanagisawa M, Elmqquist JK (2001) Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol 435:6–25.

McDonald C, Bullmore E, Shap PM, Chitnis X, Suckling J, MacCabe J, Walshe M, Murray RM (2005) Regional volume deviations of brain structure in schizophrenia and psychotic bipolar disorder: computational morphometry study. Br J Psychiatry 186:369–377.

Mieda M, Sakurai T (2013) Orexin (hypocretin) receptor agonists and antagonists for treatment of sleep disorders. Rationale for development and current status. CNS Drugs 27:83–90.

Miller DD (2004) Atypical antipsychotics: sleep, sedation, and efficacy. Prim Care Companion J Clin Psychiatry 6:3–7.

Moga MM, Weis RP, Moore RY (1995) Efferent projections of the subfield of the hippocampal formation by schizophrenia and related psychotic disorders. Arch Gen Psychiatry 66:938–946.

Moore H, Jentsch JD, Ghajarnia M, Geyer MA, Grace AA (2006) A neurobehavioral systems analysis of adult rats exposed to methyloxazymethanol acetate on E17: implications for the neuropathology of schizophrenia. Biol Psychiatry 60:253–264.

Moorman DE, Aston-Jones G (2010) Orexin/hypocretin modulates response of ventral tegmental dopamine neurons to prefrontal activation: diurnal influences. J Neurosci 30:15585–15599.

Muench J, Hamer AM (2010) Adverse effects of antipsychotic medications. Am Fam Physician 81:617–622.

Murase S, Grehoff J, Chouvet G, Gonon FG, Svensson TH (1993) Prefrontal cortex regulates burst firing and transmitter release in rat mesolimbic dopamine neurons studied in vivo. Neurosci Lett 157:53–56.

Nakamura T, Uramura K, Nambu T, Yada T, Goto K, Yanagisawa M, Sakurai T (2000) Orexin-induced hyperlocomotion and stereotypy are mediated by the dopaminergic system. Brain Res 873:181–187.

Parsons MP, Li S, Kirovac GJ (2007) Functional and anatomical connection between the paraventricular nucleus of the thalamus and dopamine fibers of the nucleus accumbens. J Comp Neurol 500:1050–1063.

Pasumarthi RK, Fadel J (2008) Activation of orexin/hypocretin projections to basal forebrain and paraventricular thalamus by acute nicotine. Brain Res Bull 77:367–373.

Penzo MA, Robert V, Tucciarone J, De Bundel D, Wang M, Van Aelst L, Darvas M, Parada LF, Palmer DT, He M, Huang ZJ, Li J (2015) The paraventricular thalamus controls a central amygdala fear circuit. Nature 519:455–459.

Perez SM, Aguilar DD, Neary JL, Carless MA, Giuffrida A, Lodge DJ (2016) Schizophrenia-like phenotype inherited by the F2 generation of a gestational disruption model of schizophrenia. Neuropsychopharmacology 41:477–486.

Perez SM, Boley A, Lodge DJ (2019a) Region specific knockdown of Parvalbumin or Somatostatin produces neuronal and behavioral deficits consistent with those observed in schizophrenia. Transl Psychiatry 9:264.

Perez SM, Donegan JJ, Boley AM, Aguilar DD, Giuffrida A, Lodge DJ (2019b) Ventral hippocampal overexpression of Cannabinoid Receptor Interacting Protein 1 (CNRIP1) produces a schizophrenia-like phenotype in the rat. Schizophr Res 206:263–270.

Perez SM, Lodge DJ (2018) Convergent inputs from the hippocampus and thalamus to the nucleus accumbens regulate dopamine neuron activity. J Neurosci 38:10607–10618.

Perez SM, Lodge DJ (2019) Adolescent stress contributes to aberrant dopamine signaling in a heritable rodent model of susceptibility. Prog Neuropsychopharmacol Biol Psychiatry 95:109701.

Pergola G, Selvaggi P, Trizio S, Bertolino A, Blasi G (2015) The role of Parvalbumin or Somatostatin produces neuronal and behavioral deficits consistent with those observed in schizophrenia. Transl Psychiatry 9:264.

Pinto A, Jankowski M, Sesack SR (2003) Projections from the paraventricular nucleus of the thalamus to the rat prefrontal cortex and nucleus accumbens shell: ultrastructural characteristics and spatial relationships with dopamine afferents. J Comp Neurol 459:142–155.

Rhyne DN, Anderson SL (2015) Suvorexant in insomnia: efficacy, safety and place in therapy. Ther Adv Drug Saf 6:189–195.

Schobal SA, Lewandowski NM, Corcoran CM, Moore H, Brown T, Malaspina D, Small SA (2009) Differential targeting of the CA1 subfield of the hippocampal formation by schizophrenia and related psychotic disorders. Arch Gen Psychiatry 66:938–946.

Shah A, Lodge DJ (2013) A loss of hippocampal perineuronal nets mediates response of ventral tegmental dopamine neurons to prefrontal activation: diurnal influences. J Neurosci 30:15585–15599.
ameliorates aging-induced changes in behavior and energy expenditure. Am J Physiol Regul Integr Comp Physiol 316:R571–R583.

Su HS, Bentivoglio M (1990) Thalamic midline cell populations projecting to the nucleus accumbens, amygdala, and hippocampus in the rat. J Comp Neurol 297:582–593.

Winrow CJ, Tanis KQ, Reiss DR, Rigby AM, Uslaner JM, Uebele VN, Doran SM, Fox SV, Garson SL, Gotter AL, Levine DM, Roecker AJ, Coleman PJ, Koblan KS, Renger JJ (2010) Orexin receptor antagonism prevents transcriptional and behavioral plasticity resulting from stimulant exposure. Neuropharmacology 58:185–194.

Zahm DS (2000) An integrative neuroanatomical perspective on some subcortical substrates of adaptive responding with emphasis on the nucleus accumbens. Neurosci Biobehav Rev 24:85–105.

Zahm DS, Heimer L (1990) Two transpallidal pathways originating in the rat nucleus accumbens. J Comp Neurol 302:437–446.